Posted by Michael Wonder on 10 Apr 2022
Amphastar receives FDA approval for ganirelix acetate injection
8 April 2022 - Amphastar Pharmaceuticals announced that the U.S. FDA has approved the Company's abbreviated new drug application for ganirelix acetate 250 mg/0.5 mL solution in a pre-filled syringe for injection.
Ganirelix acetate injection is indicated for the inhibition of premature luteinising hormone surges in women undergoing controlled ovarian hyperstimulation.
